Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results

Abstract Background Endocrine resistance is a major challenge in treating patients with ER+ /HER2− metastatic breast cancer (MBC) necessitating a switch from endocrine therapy to more toxic therapies. Mutations in ESR1 constitute a key mechanism of resistance to endocrine therapy in ER+ /HER2− BC. T...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Erika P. Hamilton, Manish R. Patel, Virginia F. Borges, Jane L. Meisel, Meena Okera, Carlos A. Alemany, Timothy J. Pluard, Robert Wesolowski, Dhanusha Sabanathan, Kathy D. Miller, Alison K. Conlin, Nicole McCarthy, Morena Shaw, Margaret Tonda, Mark Shilkrut, Nancy U. Lin
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-07-01
coleção:	Breast Cancer Research
Assuntos:	Complete estrogen receptor antagonist Selective estrogen receptor degrader Estrogen receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer Endocrine therapy Palazestrant Estrogen receptor mutation
Acesso em linha:	https://doi.org/10.1186/s13058-025-02049-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!